Literature DB >> 29199004

Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer.

Zongyuan Yang1, Ping Jin1, Sen Xu1, Taoran Zhang1, Xin Yang1, Xiaoting Li1, Xiao Wei1, Chaoyang Sun1, Gang Chen1, Ding Ma1, Qinglei Gao2.   

Abstract

Inflammation and host stromal activation contribute significantly to ovarian cancer (OC) initiation and malignant progression. However, the complex reciprocal interactions between them are largely unknown. Here, we discovered that the tumor suppressor gene Dicer was paradoxically overexpressed in ovarian tumor stroma, and induced fibroblast activation and stromal inflammation. Dicer transformed normal fibroblasts to a carcinoma-associated fibroblast (CAF)-like state, which was morphologically spread out and functionally activated to fuel tumor invasion and metastasis. Attenuation of Dicer hampered CAF characteristics, diminished stromal inflammation and the role of fibroblasts in supporting tumor growth. Moreover, Dicer drove the expression of an "inflammatory signature" in fibroblasts that could be used to discriminate normal and cancerous stroma and predict the survival of patients with OC. Finally, the nuclear factor κ B (NFκB) signaling was demonstrated to be responsible for Dicer effect on fibroblast activation and stromal inflammation, through microRNA (miR)-6780b. Our study represents the first report that characterizes Dicer expression and function in the tumor stroma, and highlights its pro-metastatic role in this context. Additionally, we suggest that the Dicer-miR6780b-NFκB cascade is an attractive target of choice in stroma-oriented OC therapy.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dicer; Inflammation; Ovarian cancer; Reprogram; Stromal fibroblast

Mesh:

Substances:

Year:  2017        PMID: 29199004     DOI: 10.1016/j.canlet.2017.11.026

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Heat shock factor 1 in cancer-associated fibroblasts is a potential prognostic factor and drives progression of oral squamous cell carcinoma.

Authors:  Qiong Wang; Yu-Chao Zhang; Li-Fang Zhu; Lu Pan; Miao Yu; Wei-Li Shen; Bang Li; Wei Zhang; Lai-Kui Liu
Journal:  Cancer Sci       Date:  2019-04-11       Impact factor: 6.716

Review 2.  Noncoding RNAs in the Interplay between Tumor Cells and Cancer-Associated Fibroblasts: Signals to Catch and Targets to Hit.

Authors:  Martina Tassinari; Paolo Gandellini
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

3.  Network Pharmacology, Molecular Docking, and Experimental Validation to Unveil the Molecular Targets and Mechanisms of Compound Fuling Granule to Treat Ovarian Cancer.

Authors:  Zhaoyi Li; Qingling Liu; Ying Zhu; Lichao Wu; Wenhong Liu; Junfeng Li; Zhiqian Zhang; Fangfang Tao
Journal:  Oxid Med Cell Longev       Date:  2022-08-23       Impact factor: 7.310

4.  The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation.

Authors:  Andrew J McKenzie; Stephanie R Hicks; Kathryn V Svec; Hannah Naughton; Zöe L Edmunds; Alan K Howe
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

5.  Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer.

Authors:  Huiran Yue; Jieyu Wang; Ruifang Chen; Xiaoman Hou; Jun Li; Xin Lu
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

Review 6.  The Role of microRNAs in Epithelial Ovarian Cancer Metastasis.

Authors:  Vu Hong Loan Nguyen; Chenyang Yue; Kevin Y Du; Mohamed Salem; Jacob O'Brien; Chun Peng
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

Review 7.  Tumor-Derived Extracellular Vesicles Regulate Cancer Progression in the Tumor Microenvironment.

Authors:  Qianqian Bao; Qianqian Huang; Yunna Chen; Qiang Wang; Ran Sang; Lei Wang; Ying Xie; Weidong Chen
Journal:  Front Mol Biosci       Date:  2022-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.